NCT02976116View on ClinicalTrials.gov

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
NSCLC
Interventions
DRUG

Fruquintinib

Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity

DRUG

Gefitinib

Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity

Trial Locations (2)

Unknown

Shanghai Chest Hospital, Shanghai

The First Hospital of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT02976116 - A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter